Department of Internal Medicine, Cardiology Division, University of Rochester Medical Center, Rochester, NY 14642, USA.
Am J Ther. 2010 Mar-Apr;17(2):182-7. doi: 10.1097/MJT.0b013e31819e9e9a.
With the arrival of a new class of drugs for the management of hypertension comes the need to define its role. Aliskiren, an orally administered direct renin inhibitor, has been approved by the US Food and Drug Administration for the treatment of hypertension. Currently, the recommendation for choice of agent in the treatment of uncomplicated hypertension is a thiazide diuretic, and for patients with diabetic nephropathy, heart failure, or coronary artery disease, an angiotensin-converting enzyme inhibitor. Patients for whom an angiotensin-converting enzyme inhibitor is indicated who are intolerant as a result of side effects should take an angiotensin receptor blocker. A new class of medicines that specifically inhibits renin is an exciting addition to the armamentarium in the treatment of hypertension. This article explores the role of aliskiren in treating hypertension as well as its side effects and appropriate dosing.
随着管理高血压的一类新药的问世，需要明确其作用。阿利克仑，一种口服直接肾素抑制剂，已被美国食品和药物管理局批准用于治疗高血压。目前，在治疗单纯性高血压时推荐选择噻嗪类利尿剂，对于糖尿病肾病、心力衰竭或冠心病患者，推荐使用血管紧张素转换酶抑制剂。对于因副作用而不能耐受血管紧张素转换酶抑制剂的患者，应使用血管紧张素受体阻滞剂。一种专门抑制肾素的新型药物是治疗高血压的有力武器。本文探讨了阿利克仑在治疗高血压中的作用及其副作用和适当的剂量。
